Marvel Biosciences Corp.
MRVL.V
TSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -25.56% | -58.07% | -31.35% | 25.94% | 35.51% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 144.34% | 154.81% | 168.14% | 1,083.84% | 595.37% |
| Change in Net Operating Assets | -139.95% | 585.33% | 52.94% | -84.66% | -72.66% |
| Cash from Operations | -46.65% | 13.83% | 4.94% | 12.57% | 20.04% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 103.76% | 1.88% | 1.88% | 185.00% | -66.67% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 29,057.69% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -180.25% | -180.25% | -180.25% | -- | -- |
| Cash from Financing | 250.03% | 61.49% | -7.61% | 156.44% | -68.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 137.09% | 327.85% | -7.28% | 119.98% | -288.19% |